Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of NBI-921352 in SCN8A developmental and epileptic encephalopathy
2021-004393-62Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zandatrigine in developmental and epileptic encephalopathy 13 (DEE13) and epileptic encephalopathy, sponsored by Neurocrine Biosciences. Primary endpoint: Incidence of serious and treatment-limiting adverse events. Started Jan 2022; status: terminated.
02
Drugs
zandatrigine
03
Conditions
developmental and epileptic encephalopathy 13 (DEE13)epileptic encephalopathy
Beyond the preview
Go deeper on 2021-004393-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004393-62.